tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Moleculin Biotech assumed with a Buy at H.C. Wainwright

H.C. Wainwright assumed coverage of Moleculin Biotech (MBRX) with a Buy rating and $4 price target Moleculin is a clinical-stage biotech company advancing treatments for highly resistant cancers and viruses, the analyst tells investors in a research note. The firm says the MIRACLE Part A data could position annamycin for accelerated approval in second-line acute myeloid leukemia.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1